Abstract:OBJECTIVE:To retrospectively analyze epidermal growth factor receptor (EGFR) gene mutation frequencies and distribution characteristics in Chinese patients with non-small-cell lung carcinoma (NSCLC) by direct gene sequencing. METHODS:Clinical samples from 443 NSCLC patients were obtained for EGFR gene mutation analysis, including 299 surgical specimens, 59 core biopsies and 85 fine needle aspiration and pleural effusion cytology specimens. All samples were processed from paraffin embedded blocks and microdissection was performed to enrich tumor cells. PCR based direct gene sequencing was used to investigate tyrosine kinase domain coding region involving exon 18 through 21. RESULTS:(1) Among 443 samples, 193 mutations were detected in 189 patients (42.7%) and 4 patients possessed two mutations involving two different exons in their tumor samples. The percentage of mutations involving exon 18 to 21 were 2.0% (4/193), 48.7% (94/193), 6.7% (13/193) and 42.5% (82/193) respectively. (2) There was no significant correlation of EGFR mutation with age, however, mutation rate (50.9%, 54/106) of exon 21 in patients over median age 57 was higher than that of the younger patients (32.2%, 28/87; P<0.01). (3) EGFR mutation rate was remarkably higher in female patients (53.5%, 107/200) than in male patients (33.7%, 82/243; P<0.01). (4) Mutation rate in adenocarcinomas (46.5%, 161/346) was much higher than in squamous cell carcinomas (13.3%, 4/30) and poorly differentiated carcinomas (24.1%, 7/29; P<0.01, P<0.05), while the adenosquamous carcinomas shared a mutation rate similar to that of adenocarcinoma (7/13, P>0.05). (5) In surgical samples, core biopsies and cytological samples, the EGFR mutation detection rates were 49.5% (148/299), 35.6% (21/59) and 23.5% (20/85) respectively. The fine needle aspiration and cytological samples showed much lower EGFR mutation detection rates (23.5%, 20/85) than that of surgical samples (49.5%, 148/299; P<0.01). CONCLUSIONS:(1) Direct gene sequencing is a reliable and effective method for the detection of EGFR mutations in NSCLC, particularly for unknown EGFR mutations. (2) EGFR mutations are more frequent in female patients and patients with adenocarcinoma NSCLC, involving mainly exon 19 and 21. (3) The mutation distribution in exons of EGFR gene appears age-related. (4) Detection rate of EGFR mutation varies in different sample types. Small biopsy and fine needle aspiration specimens are valuable materials for analyzing EGFR mutation in NSCLC, although rare false negativity may occur using such samples.

[Detection of Epidermal Growth Factor Receptor and C-Met Gene Copies for Prognostic Evaluation of Non-Small Cell Lung Cancer].

Clinicopathological Features and Prognostic Implications of EGFR/c-Met Gene Copy Number and Protein Expression in Non-Small Cell Lung Cancer

Comparison of the Epidermal Growth Factor Receptor Protein Expression Between Primary Non-Small Cell Lung Cancer and Paired Lymph Node Metastases: Implications for Targeted Nuclide Radiotherapy.

Prognostic Value of MET, Cyclin D1 and MET Gene Copy Number in Non-Small Cell Lung Cancer.

Comparison of the C-Met Gene Amplification Between Primary Tumor and Metastatic Lymph Nodes in Non-Small Cell Lung Cancer.

C-Met As a Molecular Marker for Esophageal Squamous Cell Carcinoma and Its Association with Clinical Outcome

[Detection of Epidermal Growth Factor Receptor Mutations in Non-Small-cell Lung Carcinoma by Direct Sequencing and Correlations with Clinicopathological Characteristics and Sample Types].

Prognostic Impact and Potential Interaction of EGFR and C-Met in the Progression of Esophageal Squamous Cell Carcinoma

EGFR Mutation is Positively Correlated with C-Met Protein Expression: a Study of 446 Resected Lung Adenocarcinoma.

Detection of MET amplification by droplet digital PCR in peripheral blood samples of non-small cell lung cancer

Prevalence of Gene Amplifications of Sox-2, C-Met, and Fgfr1 in Asian Patients with Esophageal Squamous Cell Carcinoma.

A Prospective Observational Study Evaluating the Correlation of c-MET Expression and EGFR Gene Mutation with Response to Erlotinib as Second-Line Treatment for Patients with Advanced/Metastatic Non-Small-Cell Lung Cancer

Is it feasible to detect epidermal growth factor receptor mutations in circulating tumor cells in nonsmall cell lung cancer?: A meta-analysis.

P1.02-057 Analysis of C-MET Amplification Non-Small Cell Lung Cancer Cell Blocks from Pleural Effusion

Egfr and Her2 Expression in Primary Cervical Cancers and Corresponding Lymph Node Metastases: Implications for Targeted Radiotherapy

Reliability of Using Circulating Tumor Cells for Detecting Epidermal Growth Factor Receptor Mutation Status in Advanced Non-Small-cell Lung Cancer Patients: a Meta-Analysis and Systematic Review

Detection of MET and SOX2 Amplification by Quantitative Real-Time PCR in Non-Small Cell Lung Carcinoma

Relationship between epidermal growth factor receptor and the prognosis of non-small cell lung cancer

[The Association Between EGFR Gene Amplification and the Prognosis in Non-small Cell Lung Cancer: A Meta-Analysis.].

Epidermal growth factor receptor gene copy number in Chinese patients with non-small cell lung cancer and clinical significance

Expressions of cyclooxygenase-2 and epidermal growth factor receptor in non-small cell lung cancer